Safety and Immunogenicity of V114 in Healthy Infants in South Korea (V114-036)

  • End date
    Mar 2, 2023
  • participants needed
  • sponsor
    Merck Sharp & Dohme Corp.
Updated on 28 August 2021


The primary purpose of this phase 3, single-arm, open-label study is to evaluate the safety and immunogenicity of a 4-dose regimen of V114 administered to healthy infants in South Korea.

Condition Pneumococcal infection, Pneumococcal Disease, streptococcus pneumoniae infections, pneumococcal infections
Treatment V114
Clinical Study IdentifierNCT04633226
SponsorMerck Sharp & Dohme Corp.
Last Modified on28 August 2021


Yes No Not Sure

Inclusion Criteria

is a healthy South Korean male or female who is 42 to 90 days of age at the time of signing informed consent
has a parent or legally acceptable representative who understands study procedures, alternative treatments available, and risks involved and voluntarily agrees to participate by signing informed consent

Exclusion Criteria

has a history of invasive pneumococcal disease or known history of other culture positive pneumococcal disease
has known hypersensitivity to pneumococcal conjugate vaccine, any licensed pediatric vaccine to be administered concomitantly, or any diphtheria toxoid-containing vaccine
has had a recent febrile illness (rectal temperature 38.1C [100.5F] or axillary temperature 37.8C [100.0F]) within 72 hours prior to receipt of study vaccine
has known or suspected impairment of immunological function
has or his/her mother has human immunodeficiency virus (HIV) infection
has or his/her mother has hepatitis B surface antigen-positive test
has known or history of functional or anatomic asplenia
has a history of autoimmune disease
has a history or suspected history of neurological disorder
has received a pneumococcal vaccine prior to study entry
has received, or is anticipated to need, corticosteroid therapy
has received a blood transfusion of immunoglobulin products
has participated in another clinical study of an investigational product
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note